Optimization of rhein-loaded polymeric nanoparticles using a factorial design and evaluation of the cytotoxic and anti-inflammatory effects

References

• Lorenz H, Richter W. Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem. 2006;40:35–163.
   Google Scholar
• Palazzo C, Ravaud J-F, Papelard A, et al. The burden of musculoskeletal conditions. PLoS One. 2014;9:1–9.
   Google Scholar
• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum. 2008;58:15–25.
   PubMed Web of Science ®Google Scholar
• Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323–1330.
   PubMed Web of Science ®Google Scholar
• Birtwhistle R, Morkem R, Peat G, et al. Prevalence and management of osteoarthritis in primary care: an epidemiologic cohort study from the Canadian primary care sentinel surveillance network. CMAJ Open. 2015;3:E270–E275.
   PubMedGoogle Scholar
• Prieto-Alhambra D, Judge A, Javaid MK, et al. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73:1659–1664.
   PubMed Web of Science ®Google Scholar
• Chopra A. The COPCORD world of musculoskeletal pain and arthritis. Rheumatology (Oxford). 2013;52:1925–1928.
   PubMed Web of Science ®Google Scholar
• Yang C-Y, Chanalaris A, Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis – looking beyond the “usual suspects”. Osteoarthritis Cartilage. 2017;25:1000–1009.
   PubMed Web of Science ®Google Scholar
• Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007;213:626–634.
   PubMed Web of Science ®Google Scholar
• Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev. 2006;58:226–242.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions (UK). Osteoarthritis: National Clinical Guideline for care and management in adults. NICE Clinical Guidelines, No. 59. London (UK): Royal College of Physicians; 2008.
   Google Scholar
• Fernandes L, Hagen KB, Bijlsma JWJ, et al. Eular recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013;72:1125–1135.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Leeb BF, et al. Eular evidence-based recommendations for the management of hand osteoarthritis: report of a task force of the Eular standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:377–388.
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Pelletier J-P. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010;2:95–104.
   PubMedGoogle Scholar
• Louthrenoo W, Nilganuwong S, Aksaranugraha S, et al. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007;15:605–614.
   PubMed Web of Science ®Google Scholar
• Bartels E, Bliddal H, Schøndorff P, et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2010;18:289–296.
   PubMed Web of Science ®Google Scholar
• Nicolas P, Tod M, Padoin C, et al. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet. 1998;35:347–359.
   PubMed Web of Science ®Google Scholar
• Nota informativa. Diacereína: Restricciones de uso tras la reexaminación de la información. Comité para la Evaluación de Riesgos en Farmacovigilancia europeo-PRAC. Agencia española de medicamentos y productos sanitarios AEMPS, Ministerio de Sanidad, servicios sociales e igualdad. 7 de marzo 2014, p. 1-2. Available from: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2014/NI-MUH_FV_03-2014-diacereina.htm
   Google Scholar
• Schumacher HR, Chen LX. Injectable corticosteroids in treatment of arthritis of the knee. Am J Med. 2005;118:1208–1214.
   PubMed Web of Science ®Google Scholar
• Go´mez-Gaete C. Nanoparti´culas polime´ricas: tecnologi´a y aplicaciones farmace´uticas. Sociedad Farmacologi´a Chile. 2014;7:7–16.
   Google Scholar
• Kroll A, Pillukat MH, Hahn D, et al. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur J Pharm Biopharm. 2009;72:370–377.
   PubMed Web of Science ®Google Scholar
• Shayne G. Alternatives to in vivo studies in toxicology. General Appl Toxicol. 1999;1:178–182.
   Google Scholar
• Lee H-M, Shin D-M, Song H-M, et al. Nanoparticles up-regulate tumor necrosis factor alpha and cxcl8 via reactive oxygen species and mitogen-activated protein kinase activation. Toxicol Appl Pharmacol. 2009;238:160–169.
   PubMed Web of Science ®Google Scholar
• Gómez-Gaete C, Retamal M, Chávez C, et al. Development, characterization and in vitro evaluation of biodegradable rhein-loaded microparticles for treatment of osteoarthritis. Eur J Pharm Sci. 2017;96:390–397.
   PubMed Web of Science ®Google Scholar
• McCall RL, Sirianni RW. PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS. J Vis Exp. 2013;82:51015.
   Google Scholar
• Fessi H, Puisieux F, Devissaguet JP, et al. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55:1–4.
   Web of Science ®Google Scholar
• Chávez C. Nueva estrategia para el tratamiento de la inflamación: microencasulación de rhein. Concepción (Chile): Universidad de Concepción; 2014.
   Google Scholar
• Li M, Rouaud O, Poncelet D. Microencapsulation by solvent evaporation: state of the art for process engineering approaches. Int J Pharm. 2008;363:26–39.
   PubMed Web of Science ®Google Scholar
• dos Santos KC, da Silva MFG, Pereira-Filho ER, et al. Polymeric nanoparticles loaded with the 3,5,3’-triiodothyroacetic acid (Triac), a thyroid hormone: factorial design, characterization, and release kinetics. Nanotechnol Sci Appl. 2012;5:37–48.
   PubMedGoogle Scholar
• Song X, Zhao Y, Hou S, et al. Dual agents loaded plga nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 2008;69:445–453.
   PubMed Web of Science ®Google Scholar
• Nobbman U, Morfesis A. Light scattering and nanoparticles. Mater Today. 2009;12:25–54.
   Web of Science ®Google Scholar
• Song X, Zhao Y, Wu W, et al. Plga nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm. 2008;350:320–329.
   PubMed Web of Science ®Google Scholar
• Kumar MR, Bakowsky U, Lehr C. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25:1771–1777.
   PubMed Web of Science ®Google Scholar
• Butoescu N, Seemayer CA, Foti M, et al. Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis. Biomaterials. 2009;30:1772–1780.
   PubMed Web of Science ®Google Scholar
• Greis PE, Georgescu HI, Fu FH, et al. Particle-induced synthesis of collagenase by synovial fibroblasts: an immunocytochemical study. J Orthop Res. 1994;12:286–293.
   PubMed Web of Science ®Google Scholar
• Liggins RT, Cruz T, Min W, et al. Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: biocompatibility and efficacy determinations in rabbits. Inflamm Res. 2004;53:363–372.
   PubMed Web of Science ®Google Scholar
• Horisawa E, Kubota K, Tuboi I, et al. Size-dependency of dl-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res. 2002;19:132–139.
   PubMed Web of Science ®Google Scholar
• Rothenfluh DA, Bermudez H, O’Neil CP, et al. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nature Mater. 2008;7:284–254.
   Web of Science ®Google Scholar
• JD, Clogston AK. Patri. Zeta potential measurement. Totowa (NJ): Humana Press; 2011. p. 63–70.
   Google Scholar
• Kocbek P, Obermajer N, Cegnar M, et al. Targeting cancer cells using plga nanoparticles surface modified with monoclonal antibody. J Control Release. 2007;120:18–26.
   PubMed Web of Science ®Google Scholar
• Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation. Biomaterials. 2010;31:6867–6875.
   PubMed Web of Science ®Google Scholar
• Ratner B, Hoffman A, Schoen F, et al. Biomaterials science: an introduction to materials in medicine. 2nd ed. San Diego (CA): Elsevier Academic Press; 2004.
   Google Scholar
• Patil S, Sandberg A, Heckert E, et al. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28:4600–4607.
   PubMed Web of Science ®Google Scholar
• Yin Win K, Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713–2722.
   PubMed Web of Science ®Google Scholar
• Amann LC, Gandal MJ, Lin R, et al. In vitro–in vivo correlations of scalable plga-risperidone implants for the treatment of schizophrenia. Pharm Res. 2010;27:1730–1737.
   PubMed Web of Science ®Google Scholar
• Ramchandani M, Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J Control Release. 1998;54:167–175.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Hadinoto K. Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly(lactic-co-glycolic acid) nanoparticles: modifications of standard nanoparticle preparation methods. Colloids Surf A Physicochem Eng Asp. 2010;370:79–86.
   Web of Science ®Google Scholar
• Gómez-Gaete C, Fattal E, Silva L, et al. Dexamethasone acetate encapsulation into trojan particles. J Control Release. 2008;128:41–49.
   PubMed Web of Science ®Google Scholar
• Thote AJ, Gupta RB. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Nanomedicine. 2005;1:85–90.
   PubMed Web of Science ®Google Scholar
• Anton N, Jakhmola A, Vandamme TF. Trojan microparticles for drug delivery. Pharmaceutics. 2012;4:1–25.
   PubMedGoogle Scholar
• Cordeiro R, Campos E, Santos A, et al. Design and characterization of bi-soft segmented polyurethane microparticles for biomedical application. Colloids Surf B Biointerfaces. 2011;88:477–482.
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen X, Fang L, et al. Rhein exerts pro- and anti-inflammatory actions by targeting IKKbeta inhibition in LPS-activated macrophages. Free Radic Biol Med. 2014;72:104–112.
   PubMed Web of Science ®Google Scholar
• Heo S-K, Yun H-J, Noh E-K, et al. Emodin and rhein inhibit LIGHT-induced monocytes migration by blocking of ROS production. Vascul Pharmacol. 2010;53:28–37.
   PubMed Web of Science ®Google Scholar
• Moldovan F, Pelletier J, Jolicoeur F-C, et al. Diacerhein and rhein reduce the ice-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2000;8:186–196.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Mathy-Hartert M, Deberg MA, et al. Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol. 2003;65:377–388.
   PubMed Web of Science ®Google Scholar
• Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage. 1999;7:272–280.
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Mineau F, Jolicoeur FC, et al. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998;25:753–762.
   PubMed Web of Science ®Google Scholar
• Tamura T, Shirai T, Kosaka N, et al. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharm. 2002;448:81–87.
   PubMed Web of Science ®Google Scholar
• Legendre F, Bogdanowicz P, Martin G, et al. Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-ap-1 dependent pathways. Clin Exp Rheumatol. 2007;25:546–555.
   PubMed Web of Science ®Google Scholar
• Martin G, Bogdanowicz P, Domagala F, et al. Rhein inhibits interleukin-1β-induced activation of MEK/ERK pathway and DNA binding of NF-κB and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation. 2003;27:233–246.
   PubMed Web of Science ®Google Scholar
• Boileau C, Tat SK, Pelletier J-P, et al. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther. 2008;10:R71.
   PubMed Web of Science ®Google Scholar
• Domagala F, Martin G, Bogdanowicz P, et al. Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for diacerein effects in osteoarthritis. Biorheology. 2006;43:577–587.
   PubMed Web of Science ®Google Scholar
• Ozbey G, Gorczynski R, Erin N. Stability of cytokines in supernatants of stimulated mouse immune cells. Eur Cytokine Netw. 2014;25:30–34.
   PubMed Web of Science ®Google Scholar
• de Jager W, Bourcier K, Rijkers GT, et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009;10:52.
   PubMed Web of Science ®Google Scholar
• Meissner F, Molawi K, Zychlinsky A. Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol. 2008;9:866–872.
   PubMed Web of Science ®Google Scholar